Short answer
aTYR PHARMA INC (ATYR) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Preliminary liquidity of approximately $68.3 million as of March 31, 2026.
aTYR PHARMA INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary liquidity of approximately $68.3 million as of March 31, 2026
- Cash position includes cash, equivalents, restricted cash and available-for-sale investments
- Unaudited estimate subject to potentially material revision in final results
Item 7.01 · Regulation FD Disclosure
- Corporate presentation updates regulatory and clinical development of efzofitimod in pulmonary sarcoidosis
- Exhibit 99.1 contains the substantive investor-facing update
- May 11, 2026 disclosure signals ongoing advancement of efzofitimod program
Item 8.01 · Other Events
- FDA feedback redirects efzofitimod into a new Phase 3 pulmonary sarcoidosis study after EFZO-FIT results
- New trial targets up to approximately 372 patients with restrictive lung disease, narrowing the addressable population
- FVC becomes primary endpoint, with KSQ-Lung as key secondary endpoint at week 48
- Dosing increases to 5.0 mg/kg intravenously every 3 weeks for 17 doses over 54 weeks
- IND submission planned for June 2026, with enhanced safety monitoring and a data safety monitoring committee
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other aTYR PHARMA INC 8-K filings
Get the next ATYR 8-K as it lands
Follow ATYR for push alerts, or ask the research agent what this filing means.